Bifogade filer
20240612_Isofol_CFO Magnus Hurst leaves the company_Final
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
GOTHENBURG, Sweden, June 12, 2024 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces today that Magnus Hurst, Chief Financial Officer, is leaving the company at the beginning of September for family reasons.
The information in the press release is intended for investors.
Magnus Hurst has held the position as CFO on a part-time consultancy basis since January this year. During the autumn, Magnus will be going on parental leave and will therefore leave his consulting assignment in the company. Isofol is now starting a recruitment process to appoint a successor.
"I would like to thank Magnus for his work at Isofol during this period. His strong competence in financial matters paired with his leadership and personality have added a lot of value to the company. I regret that he is leaving, but fully understand the decision to devote more time to his family," says Petter Segelman Lindqvist, Isofol's CEO.
“Isofol has a goal-oriented and hard-working organisation with a clear strategy to conduct a well-tailored clinical study of arfolitixorin. It has been exciting to participate in the company's work and I want to thank Petter, the board and other employees for the trust given to me,” says Magnus Hurst, CFO of Isofol.
Magnus will continue in his role as CFO until September 2, 2024.
For more information, please contact
Isofol Medical AB (publ)
Petter Segelman Lindqvist, CEO
E-mail: petter.s.lindqvist@isofolmedical.com
Phone: +46 (0) 739 60 12 56
The information was submitted for publication, through the agency of the contact persons set out above, at 13:15 CEST on June 12, 2024.
About Isofol Medical AB (publ)
Isofol Medical AB (publ) aims to raise the quality of life and increase the survival rate for patients with severe forms of cancer. The company’s drug candidate arfolitixorin is being developed with the purpose of increasing the efficacy of standard first-line treatment for several forms of solid tumours, including colorectal cancer. The next step in the clinical development program is currently being prepared based on a new dosage regimen that is expected to optimize arfolitixorin’s efficacy. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.